Analyst Downgrades FibroGen On Questions Regarding Future Direction
Portfolio Pulse from Vandana Singh
FibroGen Inc's Phase 3 ZEPHYRUS-1 trial of pamrevlumab in idiopathic pulmonary fibrosis (IPF) failed to meet primary and secondary endpoints. William Blair downgraded the stock to Market Perform. FGEN shares are down 82.5% at $2.80.
June 26, 2023 | 6:12 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
FibroGen's failed Phase 3 trial of pamrevlumab led to a stock downgrade by William Blair. FGEN shares are down 82.5% at $2.80.
The failed Phase 3 trial of pamrevlumab in IPF has led to a lack of confidence in the company's future direction. This has resulted in a stock downgrade by William Blair and a significant drop in FGEN's share price.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100